GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » EV-to-Revenue

ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) EV-to-Revenue : 2.25 (As of May. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ImmunoPrecise Antibodies's enterprise value is $39.67 Mil. ImmunoPrecise Antibodies's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $17.60 Mil. Therefore, ImmunoPrecise Antibodies's EV-to-Revenue for today is 2.25.

The historical rank and industry rank for ImmunoPrecise Antibodies's EV-to-Revenue or its related term are showing as below:

IPA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.84   Med: 5.9   Max: 42.43
Current: 2.25

During the past 13 years, the highest EV-to-Revenue of ImmunoPrecise Antibodies was 42.43. The lowest was 1.84. And the median was 5.90.

IPA's EV-to-Revenue is ranked better than
78.09% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs IPA: 2.25

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), ImmunoPrecise Antibodies's stock price is $1.28. ImmunoPrecise Antibodies's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 was $0.70. Therefore, ImmunoPrecise Antibodies's PS Ratio for today is 1.83.


ImmunoPrecise Antibodies EV-to-Revenue Historical Data

The historical data trend for ImmunoPrecise Antibodies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies EV-to-Revenue Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec13 Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 4.01 10.91 7.47 4.15

ImmunoPrecise Antibodies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.93 4.15 4.06 3.59 3.05

Competitive Comparison of ImmunoPrecise Antibodies's EV-to-Revenue

For the Biotechnology subindustry, ImmunoPrecise Antibodies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's EV-to-Revenue falls into.



ImmunoPrecise Antibodies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ImmunoPrecise Antibodies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=39.674/17.595
=2.25

ImmunoPrecise Antibodies's current Enterprise Value is $39.67 Mil.
ImmunoPrecise Antibodies's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunoPrecise Antibodies  (NAS:IPA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ImmunoPrecise Antibodies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.28/0.698
=1.83

ImmunoPrecise Antibodies's share price for today is $1.28.
ImmunoPrecise Antibodies's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.70.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunoPrecise Antibodies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from Europe.